Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection

Monita R. Patel, M. Nana, M. Yotebieng, M. Tabala, F. Behets, A. Van Rie

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm3 or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100- 350 cells/mm3, or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤350 cells/mm3 or patient has WHO Clinical Stage 4. RESULTS : Of 492 patients, 235 (47.8%) experienced delayed initiation of ART: 171 (72.8%) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2%) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95%CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95%CI 1.08-1.33/100 cells/mm3), TB drug intolerance (aOR 1.93, 95%CI 1.23-3.02) and nondisclosure of HIV infection (aOR 1.50, 95%CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.

Original languageEnglish (US)
Pages (from-to)694-699+i
JournalInternational Journal of Tuberculosis and Lung Disease
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2014
Externally publishedYes

Fingerprint

Virus Diseases
Tuberculosis
HIV
CD4 Lymphocyte Count
Therapeutics
Democratic Republic of the Congo
Pulmonary Tuberculosis
Pharmaceutical Preparations
Primary Health Care

Keywords

  • Delay
  • HIV
  • Integration
  • Predictors
  • TB

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection. / Patel, Monita R.; Nana, M.; Yotebieng, M.; Tabala, M.; Behets, F.; Van Rie, A.

In: International Journal of Tuberculosis and Lung Disease, Vol. 18, No. 6, 01.06.2014, p. 694-699+i.

Research output: Contribution to journalArticle

Patel, Monita R. ; Nana, M. ; Yotebieng, M. ; Tabala, M. ; Behets, F. ; Van Rie, A. / Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection. In: International Journal of Tuberculosis and Lung Disease. 2014 ; Vol. 18, No. 6. pp. 694-699+i.
@article{dc808a11651844728bb90eb583da097b,
title = "Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection",
abstract = "SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm3 or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100- 350 cells/mm3, or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤350 cells/mm3 or patient has WHO Clinical Stage 4. RESULTS : Of 492 patients, 235 (47.8{\%}) experienced delayed initiation of ART: 171 (72.8{\%}) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2{\%}) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95{\%}CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95{\%}CI 1.08-1.33/100 cells/mm3), TB drug intolerance (aOR 1.93, 95{\%}CI 1.23-3.02) and nondisclosure of HIV infection (aOR 1.50, 95{\%}CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.",
keywords = "Delay, HIV, Integration, Predictors, TB",
author = "Patel, {Monita R.} and M. Nana and M. Yotebieng and M. Tabala and F. Behets and {Van Rie}, A.",
year = "2014",
month = "6",
day = "1",
doi = "10.5588/ijtld.13.0807",
language = "English (US)",
volume = "18",
pages = "694--699+i",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "6",

}

TY - JOUR

T1 - Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection

AU - Patel, Monita R.

AU - Nana, M.

AU - Yotebieng, M.

AU - Tabala, M.

AU - Behets, F.

AU - Van Rie, A.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm3 or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100- 350 cells/mm3, or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤350 cells/mm3 or patient has WHO Clinical Stage 4. RESULTS : Of 492 patients, 235 (47.8%) experienced delayed initiation of ART: 171 (72.8%) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2%) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95%CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95%CI 1.08-1.33/100 cells/mm3), TB drug intolerance (aOR 1.93, 95%CI 1.23-3.02) and nondisclosure of HIV infection (aOR 1.50, 95%CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.

AB - SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm3 or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100- 350 cells/mm3, or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤350 cells/mm3 or patient has WHO Clinical Stage 4. RESULTS : Of 492 patients, 235 (47.8%) experienced delayed initiation of ART: 171 (72.8%) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2%) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95%CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95%CI 1.08-1.33/100 cells/mm3), TB drug intolerance (aOR 1.93, 95%CI 1.23-3.02) and nondisclosure of HIV infection (aOR 1.50, 95%CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.

KW - Delay

KW - HIV

KW - Integration

KW - Predictors

KW - TB

UR - http://www.scopus.com/inward/record.url?scp=84901246881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901246881&partnerID=8YFLogxK

U2 - 10.5588/ijtld.13.0807

DO - 10.5588/ijtld.13.0807

M3 - Article

C2 - 24903941

AN - SCOPUS:84901246881

VL - 18

SP - 694-699+i

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 6

ER -